1. Home
  2. MDWD vs ARAY Comparison

MDWD vs ARAY Comparison

Compare MDWD & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.36

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Logo Accuray Incorporated

ARAY

Accuray Incorporated

HOLD

Current Price

$0.85

Market Cap

96.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
ARAY
Founded
2000
1990
Country
Israel
United States
Employees
N/A
990
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.5M
96.2M
IPO Year
2014
2007

Fundamental Metrics

Financial Performance
Metric
MDWD
ARAY
Price
$18.36
$0.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$37.50
$4.50
AVG Volume (30 Days)
79.9K
1.3M
Earning Date
11-20-2025
02-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,932,000.00
$450,902,000.00
Revenue This Year
$15.89
$3.82
Revenue Next Year
$25.33
$4.08
P/E Ratio
N/A
N/A
Revenue Growth
6.15
1.51
52 Week Low
$14.14
$0.78
52 Week High
$22.51
$2.95

Technical Indicators

Market Signals
Indicator
MDWD
ARAY
Relative Strength Index (RSI) 48.04 35.20
Support Level $18.55 $0.78
Resistance Level $19.00 $0.94
Average True Range (ATR) 0.53 0.06
MACD -0.07 -0.00
Stochastic Oscillator 16.72 22.98

Price Performance

Historical Comparison
MDWD
ARAY

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Share on Social Networks: